{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T05:27:28Z","timestamp":1777699648851,"version":"3.51.4"},"reference-count":175,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","bprclinrheum.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.berh.2015.05.010","type":"journal-article","created":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T02:24:15Z","timestamp":1435199055000},"page":"319-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases"],"prefix":"10.1016","volume":"29","author":[{"given":"Worawit","family":"Louthrenoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2015.05.010_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib2","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2015.05.010_bib3","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1046\/j.1440-1746.2000.0150121356.x","article-title":"Chronic hepatitis B virus infection in Asian countries","volume":"15","author":"Merican","year":"2000","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.berh.2015.05.010_bib4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1620\/tjem.233.129","article-title":"Prevalence of hepatitis B virus infection in patients with rheumatic diseases in tohoku area: a retrospective multicenter survey","volume":"233","author":"Watanabe","year":"2014","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.berh.2015.05.010_bib5","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/jvh.12302","article-title":"Low prevalence of hepatitis B virus infection in patients with autoimmune diseases in a Chinese patient population","volume":"21","author":"Sui","year":"2014","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.berh.2015.05.010_bib6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10067-013-2170-1","article-title":"The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis","volume":"32","author":"Zou","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib7","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1016\/j.vaccine.2009.08.048","article-title":"Epidemiological serosurvey of hepatitis B in China\u2013declining HBV prevalence due to hepatitis B vaccination","volume":"27","author":"Liang","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.berh.2015.05.010_bib8","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s10067-012-1988-2","article-title":"Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs","volume":"31","author":"Tan","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib9","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s00296-011-1934-7","article-title":"Prevalence of hepatitis B surface antigen in patients with ankylosing spondylitis and its association with HLA-B27: a retrospective study from south China","volume":"32","author":"Zheng","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2015.05.010_bib10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10067-011-1814-2","article-title":"Clinical significance of chronic hepatitis B virus infection in patients with primary Sjogren's syndrome","volume":"31","author":"Chen","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3109\/s10165-011-0458-z","article-title":"Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and\/or nonbiological disease-modifying antirheumatic drugs","volume":"21","author":"Mori","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib12","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00296-009-1188-9","article-title":"Low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus in southern China","volume":"30","author":"Zhao","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2015.05.010_bib13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.autrev.2009.02.007","article-title":"Chronic hepatitis B virus infection in Sjogren's syndrome. Prevalence and clinical significance in 603 patients","volume":"8","author":"Marcos","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2015.05.010_bib14","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3899\/jrheum.081308","article-title":"Is screening for hepatitis B and hepatitis C useful in patients with recent-onset polyarthritis? the ESPOIR cohort study","volume":"36","author":"Guennoc","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/ard.41.5.479","article-title":"Hepatitis B virus infection in patients with rheumatic diseases","volume":"41","author":"Permin","year":"1982","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib16","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.1002\/hep.22945","article-title":"Reactivation of hepatitis B","volume":"49","author":"Hoofnagle","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.berh.2015.05.010_bib17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors","volume":"62","author":"Yeo","year":"2000","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.berh.2015.05.010_bib18","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/acr.21990","article-title":"Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases","volume":"65","author":"Droz","year":"2013","journal-title":"Arthritis Care Res Hob"},{"key":"10.1016\/j.berh.2015.05.010_bib19","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1086\/496924","article-title":"Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature","volume":"41","author":"Kempinska","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib20","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1016\/j.ejca.2013.07.006","article-title":"Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group","volume":"49","author":"Kim","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.berh.2015.05.010_bib21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4174\/astr.2014.86.5.256","article-title":"High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipients","volume":"86","author":"Kim","year":"2014","journal-title":"Ann Surg Treat Res"},{"key":"10.1016\/j.berh.2015.05.010_bib22","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/jmv.10430","article-title":"Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study","volume":"70","author":"Yeo","year":"2003","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.berh.2015.05.010_bib23","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.berh.2015.05.010_bib24","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1073\/pnas.83.6.1627","article-title":"Hepatitis B virus DNA contains a glucocorticoid-responsive element","volume":"83","author":"Tur-Kaspa","year":"1986","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"10.1016\/j.berh.2015.05.010_bib25","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1111\/j.1440-1843.2010.01798.x","article-title":"Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids","volume":"15","author":"Kim","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.berh.2015.05.010_bib26","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1186\/1471-2334-13-394","article-title":"HBV reactivation in an occult HBV infection patient treated with prednisone for nephrotic syndrome: case report and literature review","volume":"13","author":"Du","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3350\/cmh.2012.18.2.225","article-title":"A\u00a0fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier","volume":"18","author":"Bae","year":"2012","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.berh.2015.05.010_bib28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s10067-013-2450-9","article-title":"Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy\u2013a report of long-term follow-up of serial cases and literature review","volume":"33","author":"Xuan","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib29","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s00296-008-0823-1","article-title":"Management of hepatitis B reactivation in patients with lupus nephritis","volume":"29","author":"Tse","year":"2009","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2015.05.010_bib30","first-page":"888","article-title":"Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate","volume":"25","author":"Gwak","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib31","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/1529-0131(200102)44:2<339::AID-ANR51>3.0.CO;2-Q","article-title":"Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient","volume":"44","author":"Ito","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2007.10.011","article-title":"Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection","volume":"38","author":"Carroll","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10067-013-2385-1","article-title":"Anti-TNF therapy in patients with HBV infection\u2013analysis of 87 patients with inflammatory arthritis","volume":"33","author":"Ye","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10067-012-1960-1","article-title":"Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFalpha agents: a retrospective analysis of 49 cases","volume":"31","author":"Ryu","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib35","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1136\/ard.2010.148783","article-title":"Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy","volume":"70","author":"Lan","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib36","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00535-010-0367-5","article-title":"Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts","volume":"46","author":"Tamori","year":"2011","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.berh.2015.05.010_bib37","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/acr.20130","article-title":"Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative\/anti-hepatitis B core antigen positive) with rheumatic diseases","volume":"62","author":"Caporali","year":"2010","journal-title":"Arthritis Care Res Hob"},{"key":"10.1016\/j.berh.2015.05.010_bib38","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/ard.2009.127233","article-title":"Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection","volume":"69","author":"Vassilopoulos","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib39","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.3899\/jrheum.081324","article-title":"Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy","volume":"36","author":"Chung","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib40","doi-asserted-by":"crossref","first-page":"926836","DOI":"10.1155\/2014\/926836","article-title":"HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-alpha) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis","volume":"2014","author":"Cantini","year":"2014","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib41","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00296-009-1202-2","article-title":"Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis","volume":"31","author":"Pyrpasopoulou","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2015.05.010_bib42","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ndt\/gfn430","article-title":"Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients","volume":"24","author":"Lovric","year":"2009","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.berh.2015.05.010_bib43","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1136\/annrheumdis-2012-202088","article-title":"Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection","volume":"72","author":"Mitroulis","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/rheumatology\/ket221","article-title":"Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection","volume":"53","author":"Fanouriakis","year":"2014","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2015.05.010_bib45","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/acr.21654","article-title":"Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B","volume":"64","author":"Kim","year":"2012","journal-title":"Arthritis Care Res Hob"},{"key":"10.1016\/j.berh.2015.05.010_bib46","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3899\/jrheum.091220","article-title":"Tocilizumab for rheumatoid arthritis with chronic hepatitis B virus infection without antiviral therapy","volume":"37","author":"Nagashima","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib47","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3109\/s10165-011-0470-3","article-title":"A\u00a0patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B","volume":"21","author":"Tsuboi","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/s10165-010-0365-8","article-title":"Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis","volume":"21","author":"Kishida","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib49","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"Suppl. 2","key":"10.1016\/j.berh.2015.05.010_bib50","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011","volume":"71","author":"Furst","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib51","doi-asserted-by":"crossref","first-page":"R179","DOI":"10.1186\/ar2868","article-title":"Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients","volume":"11","author":"Charpin","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2015.05.010_bib52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","article-title":"Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy","volume":"131","author":"Hui","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.berh.2015.05.010_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/14397595.2013.852834","article-title":"A\u00a0proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy","volume":"24","author":"Harigai","year":"2014","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib54","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2015.05.010_bib55","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/hep.27248","article-title":"Spatial epidemiology of hepatitis C virus infection in Egypt: analyses and implications","volume":"60","author":"Cuadros","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.berh.2015.05.010_bib56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.disamonth.2014.04.002","article-title":"Hepatitis C","volume":"60","author":"Chan","year":"2014","journal-title":"Dis Mon"},{"key":"10.1016\/j.berh.2015.05.010_bib57","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jbspin.2011.05.019","article-title":"Usefulness of routine hepatitis C and hepatitis B serology in the diagnosis of recent-onset arthritis. Systematic prospective screening in all patients seen by the rheumatologists of a defined area\u2013brief report","volume":"79","author":"Ansemant","year":"2012","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.berh.2015.05.010_bib58","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1007\/s00296-011-2014-8","article-title":"Prevalence and clinical presentations of hepatitis C virus among patients admitted to the rheumatology ward","volume":"32","author":"El Garf","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2015.05.010_bib59","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/MEG.0b013e328324ed47","article-title":"Prevalence of hepatitis C virus antibodies in systemic lupus erythematosus","volume":"21","author":"Mohan","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.berh.2015.05.010_bib60","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.autrev.2008.07.003","article-title":"Hepatitis C virus infection and primary Sjogren's syndrome: a clinical and serologic description of 9 patients","volume":"8","author":"Ceribelli","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2015.05.010_bib61","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00000441-200605000-00003","article-title":"Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus","volume":"331","author":"Ahmed","year":"2006","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.berh.2015.05.010_bib62","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1590\/S0100-879X2005000500020","article-title":"Hepatitis C virus seroprevalence and genotypes in patients with diffuse connective tissue diseases and spondyloarthropathies","volume":"38","author":"Barbosa","year":"2005","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.berh.2015.05.010_bib63","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/art.21079","article-title":"Hepatitis C virus infection in psoriatic arthritis","volume":"53","author":"Palazzi","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib64","first-page":"1016","article-title":"Hepatitis C virus and rheumatoid arthritis: further pieces to the puzzle","volume":"31","author":"Csepregi","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib65","first-page":"455","article-title":"Prevalence of rheumatoid arthritis and hepatitis C in those age 60 and older in a US population based study","volume":"30","author":"Hsu","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib66","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.61.7.635","article-title":"Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis","volume":"61","author":"Maillefert","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib67","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1002\/1529-0131(200012)43:12<2801::AID-ANR21>3.0.CO;2-V","article-title":"Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus","volume":"43","author":"Ramos-Casals","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib68","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0168-8278(99)80127-5","article-title":"Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome","volume":"30","author":"Munoz-Rodriguez","year":"1999","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.berh.2015.05.010_bib69","doi-asserted-by":"crossref","first-page":"871401","DOI":"10.1155\/2012\/871401","article-title":"Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection","volume":"2012","author":"Himoto","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.berh.2015.05.010_bib70","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/ar1041","article-title":"Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement","volume":"6","author":"Bombardieri","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2015.05.010_bib71","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/hepr.12014","article-title":"Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy","volume":"43","author":"Watanabe","year":"2013","journal-title":"Hepatol Res"},{"key":"10.1016\/j.berh.2015.05.010_bib72","first-page":"363","article-title":"Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis","volume":"18","author":"Mok","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib73","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14656560902731951","article-title":"Treatment strategies for a patient with rheumatoid arthritis and hepatitis C","volume":"10","author":"Giannitti","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.berh.2015.05.010_bib74","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/ker190","article-title":"Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review","volume":"50","author":"Brunasso","year":"2011","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2015.05.010_bib75","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res Hob"},{"key":"10.1016\/j.berh.2015.05.010_bib76","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10067-013-2378-0","article-title":"Long-term safety of anti-TNF-alpha in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients","volume":"33","author":"Costa","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib77","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A\u00a0randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib78","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jmii.2011.12.020","article-title":"Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis","volume":"46","author":"Lin","year":"2013","journal-title":"J\u00a0Microbiol Immunol Infect"},{"key":"10.1016\/j.berh.2015.05.010_bib79","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1093\/rheumatology\/kes051","article-title":"Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection","volume":"51","author":"Dragonas","year":"2012","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2015.05.010_bib80","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00296-011-2060-2","article-title":"Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection","volume":"32","author":"Nagashima","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2015.05.010_bib81","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/ar3865","article-title":"Current treatment of hepatitis C-associated rheumatic diseases","volume":"14","author":"Ferri","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2015.05.010_bib82","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-065X.2012.01131.x","article-title":"Janus-like effects of type I interferon in autoimmune diseases","volume":"248","author":"Axtell","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.berh.2015.05.010_bib83","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nrrheum.2009.237","article-title":"Type I interferons: crucial participants in disease amplification in autoimmunity","volume":"6","author":"Hall","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib84","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/BOR.0b013e3283368099","article-title":"Interferon therapy in rheumatic diseases: state-of-the-art 2010","volume":"22","author":"Kotter","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib85","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0168-8278(96)80113-9","article-title":"Side effects of high-dose interferon therapy for chronic hepatitis C","volume":"25","author":"Okanoue","year":"1996","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.berh.2015.05.010_bib86","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3109\/08916930903510971","article-title":"Type I interferon therapy and its role in autoimmunity","volume":"43","author":"Biggioggero","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.berh.2015.05.010_bib87","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/RHU.0b013e31821557e7","article-title":"Interferon-alpha induced lupus in a patient with chronic hepatitis C virus","volume":"17","author":"Rizvi","year":"2011","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib88","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.jp.7211342","article-title":"Neonatal lupus and IUGR following alpha-interferon therapy during pregnancy","volume":"25","author":"Fritz","year":"2005","journal-title":"J\u00a0Perinatol"},{"key":"10.1016\/j.berh.2015.05.010_bib89","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0049-0172(98)80015-2","article-title":"Alpha-interferon-induced arthritis: clinical presentation treatment, and prevention","volume":"27","author":"Nesher","year":"1998","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib90","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/1756-0500-6-437","article-title":"Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature","volume":"6","author":"Cacopardo","year":"2013","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.berh.2015.05.010_bib91","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1742-1241.2005.00651.x","article-title":"Interferon-induced sarcoidosis","volume":"60","author":"Alazemi","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.berh.2015.05.010_bib92","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14740330903066726","article-title":"Type I IFNs and their role in the development of autoimmune diseases","volume":"8","author":"Burdick","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.berh.2015.05.010_bib93","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1056\/NEJMra1201533","article-title":"Response to the AIDS pandemic\u2013a global health model","volume":"368","author":"Piot","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2015.05.010_bib94","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/BOR.0b013e3282f1fea7","article-title":"Rheumatic manifestations of human immunodeficiency virus infection","volume":"20","author":"Louthrenoo","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib95","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00124743-199710000-00004","article-title":"Musculoskeletal manifestations of HIV infection in Thailand: an analysis of 100 cases","volume":"3","author":"Louthrenoo","year":"1997","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib96","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.ejim.2007.09.020","article-title":"Rheumatoid arthritis associated to HIV infection","volume":"19","author":"Azeroual","year":"2008","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.berh.2015.05.010_bib97","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.semarthrit.2014.05.009","article-title":"Concomitant systemic lupus erythematosus and HIV: case series and literature review","volume":"44","author":"Mody","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib98","doi-asserted-by":"crossref","first-page":"19","DOI":"10.7326\/0003-4819-106-1-19","article-title":"The co-occurrence of Reiter's syndrome and acquired immunodeficiency","volume":"106","author":"Winchester","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.berh.2015.05.010_bib99","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1001\/archderm.1987.01660360050012","article-title":"Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome","volume":"123","author":"Duvic","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.berh.2015.05.010_bib100","first-page":"1243","article-title":"Successful treatment of severe Reiter's syndrome associated with human immunodeficiency virus infection with etretinate. Report of 2 cases","volume":"20","author":"Louthrenoo","year":"1993","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib101","first-page":"662","article-title":"Improvement in CD4 lymphocyte count in HIV-Reiter's syndrome after treatment with sulfasalazine","volume":"21","author":"Disla","year":"1994","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib102","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S0149-2918(96)80063-4","article-title":"Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine","volume":"18","author":"Chiang","year":"1996","journal-title":"Clin Ther"},{"key":"10.1016\/j.berh.2015.05.010_bib103","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/ard.2007.081513","article-title":"The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease","volume":"67","author":"Cepeda","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib104","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-202423","article-title":"ANCA-associated vasculitis and pauci-immune glomerulonephritis in HIV disease","author":"Evans","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.berh.2015.05.010_bib105","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1128\/AAC.02496-13","article-title":"Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in\u00a0vitro","volume":"58","author":"Gavegnano","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.berh.2015.05.010_bib106","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.semarthrit.2005.03.007","article-title":"Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease","volume":"35","author":"Calabrese","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib107","first-page":"741","article-title":"Human immunodeficiency virus-associated rheumatic disorders in the HAART era","volume":"31","author":"Marquez","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib108","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/art.21980","article-title":"Changing spectrum of the diffuse infiltrative lymphocytosis syndrome","volume":"55","author":"Basu","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib109","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/00002030-200406180-00020","article-title":"Emergence of Sjogren's syndrome in AIDS patients during highly active antiretroviral therapy","volume":"18","author":"Mastroianni","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.berh.2015.05.010_bib110","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.autrev.2014.04.005","article-title":"Autoimmune diseases in HIV-infected patients: 52 cases and literature review","volume":"13","author":"Iordache","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2015.05.010_bib111","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jmii.2013.08.002","article-title":"Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy","volume":"48","author":"Yang","year":"2015","journal-title":"J\u00a0Microbiol Immunol Infect"},{"key":"10.1016\/j.berh.2015.05.010_bib112","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.0b013e3182a3516e","article-title":"The global epidemiology of herpes zoster","volume":"81","author":"Yawn","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.berh.2015.05.010_bib113","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/0961203312470186","article-title":"Increased incidence of herpes zoster among patients with systemic lupus erythematosus","volume":"22","author":"Chakravarty","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2015.05.010_bib114","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/acr.21928","article-title":"Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study","volume":"65","author":"Veetil","year":"2013","journal-title":"Arthritis Care Res Hob"},{"key":"10.1016\/j.berh.2015.05.010_bib115","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/RHU.0b013e3181d52ed7","article-title":"Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus","volume":"16","author":"Borba","year":"2010","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib116","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United\u00a0States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib117","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/rheumatology\/kel328","article-title":"Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders","volume":"45","author":"Wolfe","year":"2006","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2015.05.010_bib118","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.amjmed.2005.06.012","article-title":"Herpes zoster in immunocompromised patients: incidence, timing, and risk factors","volume":"118","author":"Wung","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.berh.2015.05.010_bib119","first-page":"2151","article-title":"Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus","volume":"31","author":"Park","year":"2004","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib120","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2015.05.010_bib121","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib122","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2015.05.010_bib123","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jbspin.2013.07.009","article-title":"Risk of herpes\/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis","volume":"81","author":"Che","year":"2014","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.berh.2015.05.010_bib124","first-page":"962","article-title":"Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review","volume":"30","author":"Zhang","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib125","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease modifying therapy","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res Hob"},{"key":"10.1016\/j.berh.2015.05.010_bib126","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib127","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-009731","article-title":"Acute encephalomyelitis with multiple herpes viral reactivations during abatacept therapy","author":"Nakajima","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.berh.2015.05.010_bib128","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib129","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/ard.49.8.630","article-title":"High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis","volume":"49","author":"Nagasawa","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib130","first-page":"1","article-title":"Advisory committee on immunization practices centers for disease C, prevention. prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.berh.2015.05.010_bib131","doi-asserted-by":"crossref","first-page":"535738","DOI":"10.1155\/2013\/535738","article-title":"Epstein-Barr virus in systemic autoimmune diseases","volume":"2013","author":"Draborg","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.berh.2015.05.010_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12032-008-9069-8","article-title":"Spontaneous remission of \u201cmethotrexate-associated lymphoproliferative disorders\u201d after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature","volume":"26","author":"Rizzi","year":"2009","journal-title":"Med Oncol"},{"key":"10.1016\/j.berh.2015.05.010_bib133","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/jnci\/djh313","article-title":"Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas","volume":"96","author":"Feng","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.berh.2015.05.010_bib134","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib135","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib136","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.berh.2015.05.010_bib137","doi-asserted-by":"crossref","first-page":"R77","DOI":"10.1186\/ar2708","article-title":"Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies","volume":"11","author":"Miceli-Richard","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2015.05.010_bib138","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10067-007-0753-4","article-title":"Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus","volume":"27","author":"Komatsuda","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib139","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2796.2006.01618.x","article-title":"Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer?","volume":"259","author":"Soderberg-Naucler","year":"2006","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.berh.2015.05.010_bib140","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/rheumatology\/ken231","article-title":"Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population","volume":"47","author":"Takizawa","year":"2008","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2015.05.010_bib141","first-page":"649","article-title":"Incidence and clinical features of cytomegalovirus infection diagnosed by cytomegalovirus pp65 antigenemia assay during high dose corticosteroid therapy for collagen vascular diseases","volume":"24","author":"Yamashita","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib142","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/s10165-006-0470-x","article-title":"Clinical evaluation of patients with inflammatory connective tissue diseases complicated by cytomegalovirus antigenemia","volume":"16","author":"Yoda","year":"2006","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib143","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MD.0b013e31818ec711","article-title":"Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature","volume":"87","author":"Ramos-Casals","year":"2008","journal-title":"Med Baltim"},{"key":"10.1016\/j.berh.2015.05.010_bib144","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1177\/0961203314532560","article-title":"Clinical characteristics and therapy exploration of active human cytomegalovirus infection in 105 lupus patients","volume":"23","author":"Zhang","year":"2014","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2015.05.010_bib145","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/rheumatology\/keh696","article-title":"Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis","volume":"44","author":"Torre-Cisneros","year":"2005","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2015.05.010_bib146","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrrheum.2009.279","article-title":"Tumor necrosis factor blockade and the risk of viral infection","volume":"6","author":"Kim","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib147","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3899\/jrheum.100818","article-title":"Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis","volume":"38","author":"Vallet","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13365-012-0080-7","article-title":"Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies","volume":"18","author":"Bellizzi","year":"2012","journal-title":"J\u00a0Neurovirol"},{"key":"10.1016\/j.berh.2015.05.010_bib149","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project","volume":"10","author":"Carson","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.berh.2015.05.010_bib150","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/infdis\/jis668","article-title":"Immunosuppression increases JC polyomavirus large T antigen DNA load in the brains of patients without progressive multifocal leukoencephalopathy","volume":"207","author":"Bayliss","year":"2013","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib151","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","article-title":"Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases","volume":"60","author":"Molloy","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib152","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/acr.21564","article-title":"Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases","volume":"64","author":"Bharat","year":"2012","journal-title":"Arthritis Care Res Hob"},{"key":"10.1016\/j.berh.2015.05.010_bib153","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","article-title":"Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis","volume":"68","author":"Clifford","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.berh.2015.05.010_bib154","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1136\/annrheumdis-2012-201638","article-title":"Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study","volume":"71","author":"Arkema","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib155","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/art.22657","article-title":"Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease","volume":"56","author":"Calabrese","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib156","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jbspin.2011.11.002","article-title":"Progressive multifocal leukoencephalopathy in autoimmune diseases","volume":"79","author":"Palazzo","year":"2012","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.berh.2015.05.010_bib157","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2169\/internalmedicine.48.1926","article-title":"Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA)","volume":"48","author":"Kobayashi","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.berh.2015.05.010_bib158","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1136\/annrheumdis-2013-204978","article-title":"A\u00a0case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab","volume":"73","author":"Ray","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib159","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2007.11.013","article-title":"The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases","volume":"30","author":"Boren","year":"2008","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.berh.2015.05.010_bib160","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1056\/NEJM200011093431912","article-title":"The emergence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8)","volume":"343","author":"Moore","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2015.05.010_bib161","first-page":"326","article-title":"Kaposi's sarcoma in rheumatic diseases","volume":"32","author":"Louthrenoo","year":"2003","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.berh.2015.05.010_bib162","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1529-8019.2012.01523.x","article-title":"Kaposi's sarcoma associated with treatment with adalimumab","volume":"25","author":"Amadu","year":"2012","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.berh.2015.05.010_bib163","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.intimp.2010.04.016","article-title":"Kaposi's sarcoma in a psoriatic arthritis patient treated with infliximab","volume":"10","author":"Ursini","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.berh.2015.05.010_bib164","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40261-013-0159-9","article-title":"Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma","volume":"34","author":"Ingegnoli","year":"2014","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.berh.2015.05.010_bib165","first-page":"453","article-title":"Diseases caused by human papillomaviruses (HPV)","volume":"7","author":"Handisurya","year":"2009","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"10.1016\/j.berh.2015.05.010_bib166","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.ogx.0000221010.82943.8c","article-title":"Human papillomavirus: the burden of infection","volume":"61","author":"Wiley","year":"2006","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.berh.2015.05.010_bib167","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1473-3099(09)70108-2","article-title":"Clinician's guide to human papillomavirus immunology: knowns and unknowns","volume":"9","author":"Einstein","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.berh.2015.05.010_bib168","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0961203311425517","article-title":"Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis","volume":"21","author":"Rojo-Contreras","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2015.05.010_bib169","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.autrev.2014.03.001","article-title":"Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature","volume":"13","author":"Zard","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2015.05.010_bib170","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3899\/jrheum.090644","article-title":"Natural history of cervical papilloma virus infection in systemic lupus erythematosus \u2013 a prospective cohort study","volume":"37","author":"Tam","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib171","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10067-010-1606-0","article-title":"Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review","volume":"30","author":"Santana","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib172","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3899\/jrheum.130170","article-title":"Herpes zoster vaccination in SLE: a pilot study of immunogenicity","volume":"40","author":"Guthridge","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib173","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/0961203311429318","article-title":"Autoimmunity following hepatitis B vaccine as part of the spectrum of \u2018Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants\u2019 (ASIA): analysis of 93 cases","volume":"21","author":"Zafrir","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.berh.2015.05.010_bib174","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s10067-013-2266-7","article-title":"Human papillomavirus vaccine and systemic lupus erythematosus","volume":"32","author":"Gatto","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2015.05.010_bib175","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0961203311429316","article-title":"The spectrum of ASIA: \u2018autoimmune (auto-inflammatory) syndrome induced by adjuvants\u2019","volume":"21","author":"Agmon-Levin","year":"2012","journal-title":"Lupus"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694215000509?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694215000509?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T18:01:14Z","timestamp":1717956074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694215000509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":175,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1521694215000509"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2015.05.010","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2015.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}